Journal
PHARMACOGENOMICS JOURNAL
Volume 5, Issue 1, Pages 49-53Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.tpj.6500289
Keywords
pharmacogenetics; antidepressant; response; COMT; mirtazapine; paroxetine
Categories
Ask authors/readers for more resources
The catechol- O- methyltransferase ( COMT) is a major degrading enzyme in the metabolic pathways of catecholaminergic neurotransmitters such as dopamine and norepinephrine. This study investigated whether the functionally relevant Val(108/ 158)Met gene variant is associated with differential antidepressant response to mirtazapine and/ or paroxetine in 102 patients with major depression ( DSM- IV criteria) participating in a randomized clinical trial with both drugs. In patients treated with mirtazapine, but not paroxetine, allelic variations in the COMT gene were associated with differential response. COMTVAL/ VAL and COMTVAL/ MET genotype carriers showed a better response than COMTMET/ MET- bearing patients in the mirtazapine group. Moreover, carriers of the COMTVAL/ VAL or COMTVAL/ MET genotype had significantly greater HAMD- 17 ( Hamilton Rating Scale for Depression 17 item version) score reductions than COMTMET/ MET homozygotes from week 2 to 6, respectively, in the mirtazapine group. Time course of response and antidepressant efficacy of mirtazapine, but not paroxetine, seem to be influenced in a clinically relevant manner by this allelic variation within the COMT gene.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available